Tumor cells inherit from their normal precursors an extensive stress response machinery that is critical for survival in response to challenges including oxidative stress, wounding and shear stress. Kruppel-like transcription factors, including KLF4 and KLF5, are rarely affected by genetic alteration during tumorigenesis, but compose key components of the stress response machinery in normal and tumor cells and interact with critical survival pathways, including RAS, p53, survivin and the BCL2 family of cell death regulators. Within tumor cells KLF4 and KLF5 play key roles in tumor cell fate, regulating cell proliferation, cell survival and the tumor initiating properties of cancer stem-like cells. These factors can be preferentially expressed in embryonic stem cells or cancer stem-like cells. Indeed, specific KLFs represent key components of a cross regulating pluripotency network in embryonic stem cells, and induce pluripotency when coexpressed in adult cells with other Yamanaka factors. Suggesting analogies between this pluripotency network and the cancer cell adaptive reprogramming that occurs in response to targeted therapy, recent studies link KLF4 and KLF5 to adaptive prosurvival signaling responses induced by HER2-targeted therapy. We review literature supporting KLFs as shared mechanisms in stress adaptation and cellular reprogramming and address the therapeutic implications.
The high mobility group box protein SOX9 and the GLI1 transcription factor play protumorigenic roles in pancreatic ductal adenocarcinoma (PDA). In Kras transgenic mice, each of these factors are crucial for the development of PDA precursor lesions. SOX9 transcription is directly regulated by GLI1, but how SOX9 functions downstream of GLI1 is unclear. We observed positive feedback, such that SOX9-deficient PDA cells have severely repressed levels of endogenous GLI1, attributed to loss of GLI1 protein stability. SOX9 associated with the F-box domain of the SKP1/CUL1/F-box (SCF) E3 ubiquitin ligase component, b-TrCP (also known as F-box/WD repeat-containing protein 1A), and suppressed its association with SKP1 and GLI1, a substrate of SCF-b-TrCP. SOX9 also tethered b-TrCP within the nucleus and promoted its degradation. SOX9 bound to b-TrCP through the SOX9 C-terminal PQA/S domain that mediates transcriptional activation. Suppression of b-TrCP in SOX9-deficient PDA cells restored GLI1 levels and promoted SOX9-dependent cancer stem cell properties. These studies identify SOX9-GLI1 positive feedback as a major determinant of GLI1 protein stability and implicate b-TrCP as a latent SOX9-bound tumor suppressor with the potential to degrade oncogenic proteins in tumor cells.
rates of OS and DMFS were similar with 45 Gy and <45 Gy but 2-and 5-year EFS rates were significantly higher with 45 Gy (82% and 66% vs. 76% and 50% with <45 Gy, p Z 0.006). The rates of OS, DMFS, and EFS were significantly lower in patients with a tumor diameter 8 mm. In patients with a tumor depth 8 mm, the rates of DMFS and EFS were significantly lower. In patients with a tumor volume <600 mm 3 , the rates of OS, DMFS, and EFS were significantly higher. Among patients that received 45 Gy, the ones with a tumor volume <600 cm 3 had significantly higher rates of DMFS and EFS but OS was similar. In multivariate analysis, no prognostic factors were found for DMFS. However, for OS and EFS >8 mm basal tumor diameter (relative risk [RR] Z 1.6, 95% confidence interval [CI] Z 1.92-3.12, p Z 0.09; and RR Z 1.8, 95% CI Z 1.15-2.81, p Z 0.01), for EFS >8 mm depth (RR Z 1.6, 95% CI Z 1.03-2.4, p Z 0.03), and 45 Gy dose (RR Z 1.4, 95% CI Z 0.9-2.08, p Z 0.06) were negative prognostic factors. SRS/FSRT-related late toxicity was significantly higher in patients with a basal tumor diameter >8 mm and depth >8 mm (p Z 0.001 and p Z 0.04, respectively). Conclusion: Total SRS/FSRT dose and tumor diameter and depth were found prognostic factors for EFS. Toxicity rate was higher in patients with a higher tumor depth and basal diameter.
Repeated lifting tasks are often required of industrial workers. Such repetitive loading of workers’ arms throughout the workday can lead to injury and fatigue. This paper details the development and prototyping of a wearable soft robotic device to augment a worker’s arms by sensing and mimicking the contractions of their arm muscles. The device shares lifting loads with the user’s muscles to increase their lifting capacity, thereby preventing injury and reducing fatigue. The human arm contains many muscles that coordinate to produce movement. However, as a simplified proof of concept, this project developed a prototype to augment just the biceps brachii muscle since it is the primary pulling muscle used in lifting movements. Key components of the prototype include a soft robotic actuator analogous to the biceps, a control system for the actuator, and a method of attaching the actuator to the user’s arm. The McKibben-inspired pneumatic muscle was chosen as the soft actuator of the prototype. The Electromyography (EMG) and pressure sensors are used to inform a hybrid control algorithm combining PID and model-based control methods. The method and results of the design and preliminary feasibility testing of the pneumatic muscle, the controlling algorithm, and the overall prototype are discussed in this paper. Based on these results, a wearable EMG controlled soft robotic arm augmentation could feasibly increase the endurance of industrial workers performing repetitive lifting tasks.
In the treatment of CNS neoplasms, radiation therapy to high biologically effective doses is performed in both fractionated and single fraction schemes. Inevitably, normal CNS tissues are irradiated, leading to both acute and late toxicities, and demanding greater insight into normal tissue effects and development of innovative strategies for radioprotection and mitigation. For this purpose, the cerebral organoid, which recapitulates many cell types and complex architectures of the human brain, is proposed as a model system. The objective of our study was to characterize the response of cerebral organoids to high single fraction doses of photon irradiation in terms of apoptosis, DNA damage, and activation of DNA repair. Materials/Methods: Cerebral organoids were prepared from human embryonic stem cells as previously described. CNS tissue differentiation was verified by histopathology. Irradiation of organoids was accomplished using a 160 kV x-ray irradiator. Apoptosis was characterized by immunofluorescence of cleaved caspase 3 and TUNEL assay. DNA damage and repair was determined by immunofluorescence of gH2Ax foci and 53BP1. Results: While cerebral organoids demonstrated no gross morphologic changes to high single dose radiation up to 40 Gy even when incubated for several months following treatment, individual apoptotic cells were readily apparent at 72 hours after 20 Gy. High levels of gH2Ax foci and 53BP1 were observed within hours. While characterization of the kinetics of DNA repair showed significant resolution of DNA damage foci by 24 hours, many foci persisted at 72 hours alongside activation of apoptotic pathways. Choroid plexus tissue was highly resistant to radiation-induced apoptosis. Conclusion: Cerebral organoids provide a viable experimental platform to study effects of radiation in normal CNS tissues, and may potentially aid in the development of neuroprotective strategies.
equal to an AUC of 0.717 and 0.808, respectively. The radiogenomics model constructed showed an improved predictive value with an AUC of 0.832. Furthermore, the radiomics signature showed no significant value in prediction of OS. Instead, both the genomics signature alone and the radiogenomics model showed a significant predictive capability for OS. Conclusion: A radiogenomics model integrating CT radiomics signature with gene characteristics was established to improve the prediction accuracy of ER and OS in patients with EC, which would direct towards integrative system-based approaches with prognostic implications for personalized RT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.